Royal Bank of Canada’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Royal Bank of Canada’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$547K	Buy	14,322 +14,272	+28,544%	+$497K	﹤0.01%	4303
2026 Q1	$2K	Buy	+50	New	+$1.71K	﹤0.01%	6699
2024 Q4	–	Sell	-6,402	Closed	-$185K	–	7005
2024 Q3	$185K	Sell	6,402 -18,731	-75%	-$536K	﹤0.01%	4873
2024 Q2	$685K	Buy	25,133 +20,907	+495%	+$560K	﹤0.01%	3766
2024 Q1	$118K	Sell	4,226 -17,905	-81%	-$493K	﹤0.01%	5089
2023 Q4	$589K	Sell	22,131 -24	-0.1%	-$605	﹤0.01%	4131
2023 Q3	$566K	Buy	22,155 +12,447	+128%	+$329K	﹤0.01%	3939
2023 Q2	$254K	Buy	9,708 +530	+6%	+$14K	﹤0.01%	4534
2023 Q1	$240K	Sell	9,178 -7,695	-46%	-$206K	﹤0.01%	4466
2022 Q4	$463K	Sell	16,873 -25,543	-60%	-$680K	﹤0.01%	4179
2022 Q3	$1.02M	Buy	+42,416	New	+$1.1M	﹤0.01%	3439
2020 Q1	–	Sell	-400	Closed	-$9K	–	6779
2019 Q4	$9K	Hold	400	–	–	﹤0.01%	6183
2019 Q3	$8K	Hold	400	–	–	﹤0.01%	5843
2019 Q2	$8K	Sell	400 -2,600	-87%	-$54K	﹤0.01%	6101
2019 Q1	$64K	Sell	3,000 -557	-16%	-$11.6K	﹤0.01%	5038
2018 Q4	$68K	Hold	3,557	–	–	﹤0.01%	4936
2018 Q3	$84K	Buy	3,557 +2,600	+272%	+$60.3K	﹤0.01%	4950
2018 Q2	$21K	Buy	957 +400	+72%	+$8.51K	﹤0.01%	5511
2018 Q1	$12K	Hold	557	–	–	﹤0.01%	5646
2017 Q4	$12K	Hold	557	–	–	﹤0.01%	5795
2017 Q3	$11K	Hold	557	–	–	﹤0.01%	6228
2017 Q2	$12K	Hold	557	–	–	﹤0.01%	5729
2017 Q1	$11K	Sell	557 -551	-50%	-$10.7K	﹤0.01%	5923
2016 Q4	$20K	Buy	+1,108	New	+$20.8K	﹤0.01%	5758

Other funds holding FTXH

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Royal Bank of Canada's FTXH Position: Q2 2026 in Review

Royal Bank of Canada increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 28,544% in Q2 2026, buying an estimated $497K and bringing the position to 14,322 shares worth $547K. The position accounts for ﹤0.01% of the portfolio, ranked #4303.

Royal Bank of Canada first reported a position in FTXH in Q4 2016 and has held it in 24 quarters since. The position peaked at $1.02M in Q3 2022. 30 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

Royal Bank of Canada held 14,322 shares of First Trust Nasdaq Pharmaceuticals ETF worth $547K as of Q2 2026.
Royal Bank of Canada bought 14,272 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $497K.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #4303 holding.
Royal Bank of Canada first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2016 and has held it in 24 quarters since.
Royal Bank of Canada's First Trust Nasdaq Pharmaceuticals ETF position peaked at $1.02M in Q3 2022.
30 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.